Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.

By J. Collet, J. Hulot, A. Peña, E. Villard, J. Esteve, J. Silvain, L. Payot, D. Brugier, G. Cayla, F. Beygui and 3 more. The Lancet, 2009

983 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. (2013, background): “Numerous clinical studies have confirmed that CYP2C19 PMs have significantly lower anticoagulation effect of clopidogrel,which is associatedwith an increased risk of major adverse cardiovascular events (Collet et al., 2009; Mega et al., 2009; Simon et al., 2009; Sofi et al., 2011).”
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. (2009, methodology): “69) similar to that found in our study.(24) In the Therapeutic Outcomes by”